PMC:7212965 / 28703-29068 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T116","span":{"begin":132,"end":140},"obj":"Disease"},{"id":"T117","span":{"begin":296,"end":304},"obj":"Disease"},{"id":"T118","span":{"begin":342,"end":350},"obj":"Disease"}],"attributes":[{"id":"A116","pred":"mondo_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A117","pred":"mondo_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A118","pred":"mondo_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"(ALT), defined as any value above the ULN, was reported in 15.0% (95% CI, 13.6%–16.4%) of patients across 17 studies including 2711 COVID-19 patients. Abnormal bilirubin, defined as any value above the ULN, was reported in 16.7% (95% CI, 15.0%–18.5%) of patients across 10 studies including 1841 COVID-19 patients. All patients had confirmed COVID-19 by laboratory "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T45","span":{"begin":160,"end":169},"obj":"Chemical"}],"attributes":[{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_16990"}],"text":"(ALT), defined as any value above the ULN, was reported in 15.0% (95% CI, 13.6%–16.4%) of patients across 17 studies including 2711 COVID-19 patients. Abnormal bilirubin, defined as any value above the ULN, was reported in 16.7% (95% CI, 15.0%–18.5%) of patients across 10 studies including 1841 COVID-19 patients. All patients had confirmed COVID-19 by laboratory "}

{"project":"LitCovid-sentences","denotations":[{"id":"T187","span":{"begin":151,"end":314},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"(ALT), defined as any value above the ULN, was reported in 15.0% (95% CI, 13.6%–16.4%) of patients across 17 studies including 2711 COVID-19 patients. Abnormal bilirubin, defined as any value above the ULN, was reported in 16.7% (95% CI, 15.0%–18.5%) of patients across 10 studies including 1841 COVID-19 patients. All patients had confirmed COVID-19 by laboratory "}

{"project":"LitCovid-PubTator","denotations":[{"id":"659","span":{"begin":90,"end":98},"obj":"Species"},{"id":"660","span":{"begin":141,"end":149},"obj":"Species"},{"id":"661","span":{"begin":254,"end":262},"obj":"Species"},{"id":"662","span":{"begin":305,"end":313},"obj":"Species"},{"id":"663","span":{"begin":319,"end":327},"obj":"Species"},{"id":"664","span":{"begin":160,"end":169},"obj":"Chemical"},{"id":"667","span":{"begin":132,"end":140},"obj":"Disease"},{"id":"668","span":{"begin":296,"end":304},"obj":"Disease"},{"id":"669","span":{"begin":342,"end":350},"obj":"Disease"}],"attributes":[{"id":"A659","pred":"tao:has_database_id","subj":"659","obj":"Tax:9606"},{"id":"A660","pred":"tao:has_database_id","subj":"660","obj":"Tax:9606"},{"id":"A661","pred":"tao:has_database_id","subj":"661","obj":"Tax:9606"},{"id":"A662","pred":"tao:has_database_id","subj":"662","obj":"Tax:9606"},{"id":"A663","pred":"tao:has_database_id","subj":"663","obj":"Tax:9606"},{"id":"A664","pred":"tao:has_database_id","subj":"664","obj":"MESH:D001663"},{"id":"A667","pred":"tao:has_database_id","subj":"667","obj":"MESH:C000657245"},{"id":"A668","pred":"tao:has_database_id","subj":"668","obj":"MESH:C000657245"},{"id":"A669","pred":"tao:has_database_id","subj":"669","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"(ALT), defined as any value above the ULN, was reported in 15.0% (95% CI, 13.6%–16.4%) of patients across 17 studies including 2711 COVID-19 patients. Abnormal bilirubin, defined as any value above the ULN, was reported in 16.7% (95% CI, 15.0%–18.5%) of patients across 10 studies including 1841 COVID-19 patients. All patients had confirmed COVID-19 by laboratory "}